BlossomHill raises $100M in bid to repeat founders’ cancer success at Turning Point

BlossomHill Therapeutics has closed a $100 million Series B to bring three of its oncology small molecules into the clinic and collect early efficacy data around the second half of 2025.

Y. Peter Li

The San Diego biotech was created in 2020 by CEO J….
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks